title: Use of Doppler ultrasonography in the assessment of bronchodilator response in acute bronchiolitis.
abstract: Measurement of the response of acute bronchiolitis (AB) to bronchodilators relies on clinical signs and pulse oximetry. We hypothesized that Doppler ultrasonographic indices of hepatic venous flow may prove to be an objective tool in the assessment of the effect of inhaled salbutamol in infants hospitalized for AB. Previously healthy infants hospitalized for their first episode of AB were prospectively studied. Composite clinical score (CCS, retractions plus wheezing/crackles) and hemoglobin oxygen saturation (SaO(2)) were measured before, and 15-min post-salbutamol nebulization (0.15 mg/kg, minimum 1.5 mg). Peak velocities at the middle hepatic vein (PV-HV) and right renal vein (PV-RV), as well as peripheral-to-middle hepatic vein transit time (TT) of an ultrasound contrast agent were also measured by Doppler ultrasonography pre- and post-nebulization. Nineteen infants were studied. Mean CCS decreased by 0.37 (95% confidence interval [CI]: 0.08-0.66, P = 0.015) and mean SaO(2) increased by 0.68% (95%CI: 0.17-1.19, P = 0.01) post-bronchodilator treatment. Mean TT increased by 9.54 sec (95%CI: 5.95-13.13, P < 0.0001) and PV-HV increased by 16.49 cm/sec (95%CI: 9.07-23.91, P = 0.0002); PV-RV did not change. TT (r = 0.51, P = 0.009), but not PV-HV, correlated negatively with CCS. There was a strong positive correlation between pre- and post-salbutamol TT values (r = 0.92, P < 0.0001). The most likely explanation for these findings is post-salbutamol abolishment of shunting at the pulmonary capillary bed. We conclude that the peripheral-to-middle hepatic vein prolongation of TT measured by Doppler ultrasonography after salbutamol administration in infants with AB can be used as a bedside tool in the objective assessment of clinical response to medication in these patients.
authors.affiliation: Department of Radiology, University Hospital of Patras, Rio-Patras, Greece.
authors.forename: Christina
authors.initials: C
authors.lastname: Kalogeropoulou
authors.forename: Michael B
authors.initials: MB
authors.lastname: Anthracopoulos
authors.forename: Spiridon
authors.initials: S
authors.lastname: Yarmenitis
authors.forename: Theodore
authors.initials: T
authors.lastname: Kanellopoulos
authors.forename: Maria
authors.initials: M
authors.lastname: Eliopoulou
authors.forename: Dimitris
authors.initials: D
authors.lastname: Papanastasiou
mesh_terms: D000208:Acute Disease; D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage*; D001783:Blood Flow Velocity / Q000187:drug effects*; D001988:Bronchiolitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006503:Hepatic Veins / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009330:Nebulizers and Vaporizers; D011446:Prospective Studies; D012082:Renal Veins / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler / Q000379:methods*
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol